Using Global Statistical Tests in Long-Term Parkinson's Disease Clinical Trials
Identifieur interne : 000C66 ( PascalFrancis/Checkpoint ); précédent : 000C65; suivant : 000C67Using Global Statistical Tests in Long-Term Parkinson's Disease Clinical Trials
Auteurs : PENG HUANG [États-Unis] ; Christopher G. Goetz [États-Unis] ; Robert F. Woolson [États-Unis] ; Barbara Tilley [États-Unis] ; Douglas Kerr [États-Unis] ; Yuko Palesch [États-Unis] ; Jordan Elm [États-Unis] ; Bernard Ravina [États-Unis] ; Kenneth J. Bergmann [États-Unis] ; Karl Kieburtz [États-Unis]Source :
- Movement disorders [ 0885-3185 ] ; 2009.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
Abstract
Parkinson's disease (PD) impairments are multidimensional, making it difficult to choose a single primary outcome when evaluating treatments to stop or lessen the long-term decline in PD. We review commonly used multivariate statistical methods for assessing a treatment's global impact, and we highlight the novel Global Statistical Test (GST) methodology. We compare the GST to other multivariate approaches using data from two PD trials. In one trial where the treatment showed consistent improvement on all primary and secondary outcomes, the GST was more powerful than other methods in demonstrating significant improvement. In the trial where treatment induced both improvement and deterioration in key outcomes, the GST failed to demonstrate statistical evidence even though other techniques showed significant improvement. Based on the statistical properties of the GST and its relevance to overall treatment benefit, the GST appears particularly well suited for a disease like PD where disability and impairment reflect dysfunction of diverse brain systems and where both disease and treatment side effects impact quality of life. In future long term trials, use of GST for primary statistical analysis would allow the assessment of clinically relevant outcomes rather than the artificial selection of a single primary outcome.
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
Pascal:09-0431484Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Using Global Statistical Tests in Long-Term Parkinson's Disease Clinical Trials</title><author><name sortKey="Peng Huang" sort="Peng Huang" uniqKey="Peng Huang" last="Peng Huang">PENG HUANG</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Division of Oncology Biostatistics, Johns Hopkins University</s1><s2>Baltimore, Maryland</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G." last="Goetz">Christopher G. Goetz</name><affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Department of Medicine, Rush University Medical Center</s1><s2>Chicago, Illinois</s2><s3>USA</s3><sZ>2 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Illinois</region></placeName></affiliation></author><author><name sortKey="Woolson, Robert F" sort="Woolson, Robert F" uniqKey="Woolson R" first="Robert F." last="Woolson">Robert F. Woolson</name><affiliation wicri:level="2"><inist:fA14 i1="03"><s1>Department of Biostatistics, Bioinformatics, and Epidemiology, Medical University of South Carolina</s1><s2>Charleston, South Carolina</s2><s3>USA</s3><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Caroline du Sud</region></placeName></affiliation></author><author><name sortKey="Tilley, Barbara" sort="Tilley, Barbara" uniqKey="Tilley B" first="Barbara" last="Tilley">Barbara Tilley</name><affiliation wicri:level="2"><inist:fA14 i1="03"><s1>Department of Biostatistics, Bioinformatics, and Epidemiology, Medical University of South Carolina</s1><s2>Charleston, South Carolina</s2><s3>USA</s3><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Caroline du Sud</region></placeName></affiliation></author><author><name sortKey="Kerr, Douglas" sort="Kerr, Douglas" uniqKey="Kerr D" first="Douglas" last="Kerr">Douglas Kerr</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Division of Oncology Biostatistics, Johns Hopkins University</s1><s2>Baltimore, Maryland</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Palesch, Yuko" sort="Palesch, Yuko" uniqKey="Palesch Y" first="Yuko" last="Palesch">Yuko Palesch</name><affiliation wicri:level="2"><inist:fA14 i1="03"><s1>Department of Biostatistics, Bioinformatics, and Epidemiology, Medical University of South Carolina</s1><s2>Charleston, South Carolina</s2><s3>USA</s3><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Caroline du Sud</region></placeName></affiliation></author><author><name sortKey="Elm, Jordan" sort="Elm, Jordan" uniqKey="Elm J" first="Jordan" last="Elm">Jordan Elm</name><affiliation wicri:level="2"><inist:fA14 i1="03"><s1>Department of Biostatistics, Bioinformatics, and Epidemiology, Medical University of South Carolina</s1><s2>Charleston, South Carolina</s2><s3>USA</s3><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Caroline du Sud</region></placeName></affiliation></author><author><name sortKey="Ravina, Bernard" sort="Ravina, Bernard" uniqKey="Ravina B" first="Bernard" last="Ravina">Bernard Ravina</name><affiliation wicri:level="2"><inist:fA14 i1="04"><s1>Department of Neurology, University of Rochester</s1><s2>Rochester, New York</s2><s3>USA</s3><sZ>8 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Bergmann, Kenneth J" sort="Bergmann, Kenneth J" uniqKey="Bergmann K" first="Kenneth J." last="Bergmann">Kenneth J. Bergmann</name><affiliation wicri:level="2"><inist:fA14 i1="05"><s1>U.S. Food and Drug Administration</s1><s2>Silver Spring, Maryland</s2><s3>USA</s3><sZ>9 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Kieburtz, Karl" sort="Kieburtz, Karl" uniqKey="Kieburtz K" first="Karl" last="Kieburtz">Karl Kieburtz</name><affiliation wicri:level="2"><inist:fA14 i1="04"><s1>Department of Neurology, University of Rochester</s1><s2>Rochester, New York</s2><s3>USA</s3><sZ>8 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">État de New York</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">09-0431484</idno><date when="2009">2009</date><idno type="stanalyst">PASCAL 09-0431484 INIST</idno><idno type="RBID">Pascal:09-0431484</idno><idno type="wicri:Area/PascalFrancis/Corpus">000D70</idno><idno type="wicri:Area/PascalFrancis/Curation">001F49</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000C66</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Using Global Statistical Tests in Long-Term Parkinson's Disease Clinical Trials</title><author><name sortKey="Peng Huang" sort="Peng Huang" uniqKey="Peng Huang" last="Peng Huang">PENG HUANG</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Division of Oncology Biostatistics, Johns Hopkins University</s1><s2>Baltimore, Maryland</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G." last="Goetz">Christopher G. Goetz</name><affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Department of Medicine, Rush University Medical Center</s1><s2>Chicago, Illinois</s2><s3>USA</s3><sZ>2 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Illinois</region></placeName></affiliation></author><author><name sortKey="Woolson, Robert F" sort="Woolson, Robert F" uniqKey="Woolson R" first="Robert F." last="Woolson">Robert F. Woolson</name><affiliation wicri:level="2"><inist:fA14 i1="03"><s1>Department of Biostatistics, Bioinformatics, and Epidemiology, Medical University of South Carolina</s1><s2>Charleston, South Carolina</s2><s3>USA</s3><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Caroline du Sud</region></placeName></affiliation></author><author><name sortKey="Tilley, Barbara" sort="Tilley, Barbara" uniqKey="Tilley B" first="Barbara" last="Tilley">Barbara Tilley</name><affiliation wicri:level="2"><inist:fA14 i1="03"><s1>Department of Biostatistics, Bioinformatics, and Epidemiology, Medical University of South Carolina</s1><s2>Charleston, South Carolina</s2><s3>USA</s3><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Caroline du Sud</region></placeName></affiliation></author><author><name sortKey="Kerr, Douglas" sort="Kerr, Douglas" uniqKey="Kerr D" first="Douglas" last="Kerr">Douglas Kerr</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Division of Oncology Biostatistics, Johns Hopkins University</s1><s2>Baltimore, Maryland</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Palesch, Yuko" sort="Palesch, Yuko" uniqKey="Palesch Y" first="Yuko" last="Palesch">Yuko Palesch</name><affiliation wicri:level="2"><inist:fA14 i1="03"><s1>Department of Biostatistics, Bioinformatics, and Epidemiology, Medical University of South Carolina</s1><s2>Charleston, South Carolina</s2><s3>USA</s3><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Caroline du Sud</region></placeName></affiliation></author><author><name sortKey="Elm, Jordan" sort="Elm, Jordan" uniqKey="Elm J" first="Jordan" last="Elm">Jordan Elm</name><affiliation wicri:level="2"><inist:fA14 i1="03"><s1>Department of Biostatistics, Bioinformatics, and Epidemiology, Medical University of South Carolina</s1><s2>Charleston, South Carolina</s2><s3>USA</s3><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Caroline du Sud</region></placeName></affiliation></author><author><name sortKey="Ravina, Bernard" sort="Ravina, Bernard" uniqKey="Ravina B" first="Bernard" last="Ravina">Bernard Ravina</name><affiliation wicri:level="2"><inist:fA14 i1="04"><s1>Department of Neurology, University of Rochester</s1><s2>Rochester, New York</s2><s3>USA</s3><sZ>8 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Bergmann, Kenneth J" sort="Bergmann, Kenneth J" uniqKey="Bergmann K" first="Kenneth J." last="Bergmann">Kenneth J. Bergmann</name><affiliation wicri:level="2"><inist:fA14 i1="05"><s1>U.S. Food and Drug Administration</s1><s2>Silver Spring, Maryland</s2><s3>USA</s3><sZ>9 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Kieburtz, Karl" sort="Kieburtz, Karl" uniqKey="Kieburtz K" first="Karl" last="Kieburtz">Karl Kieburtz</name><affiliation wicri:level="2"><inist:fA14 i1="04"><s1>Department of Neurology, University of Rochester</s1><s2>Rochester, New York</s2><s3>USA</s3><sZ>8 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">État de New York</region></placeName></affiliation></author></analytic><series><title level="j" type="main">Movement disorders</title><title level="j" type="abbreviated">Mov. disord.</title><idno type="ISSN">0885-3185</idno><imprint><date when="2009">2009</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Movement disorders</title><title level="j" type="abbreviated">Mov. disord.</title><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Clinical trial</term><term>Long term test</term><term>Nervous system diseases</term><term>Parkinson disease</term><term>Prognosis</term><term>Statistical test</term><term>Treatment</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Maladie de Parkinson</term><term>Pathologie du système nerveux</term><term>Test statistique</term><term>Essai longue durée</term><term>Essai clinique</term><term>Pronostic</term><term>Traitement</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Parkinson's disease (PD) impairments are multidimensional, making it difficult to choose a single primary outcome when evaluating treatments to stop or lessen the long-term decline in PD. We review commonly used multivariate statistical methods for assessing a treatment's global impact, and we highlight the novel Global Statistical Test (GST) methodology. We compare the GST to other multivariate approaches using data from two PD trials. In one trial where the treatment showed consistent improvement on all primary and secondary outcomes, the GST was more powerful than other methods in demonstrating significant improvement. In the trial where treatment induced both improvement and deterioration in key outcomes, the GST failed to demonstrate statistical evidence even though other techniques showed significant improvement. Based on the statistical properties of the GST and its relevance to overall treatment benefit, the GST appears particularly well suited for a disease like PD where disability and impairment reflect dysfunction of diverse brain systems and where both disease and treatment side effects impact quality of life. In future long term trials, use of GST for primary statistical analysis would allow the assessment of clinically relevant outcomes rather than the artificial selection of a single primary outcome.</div></front></TEI><inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0></fA01><fA03 i2="1"><s0>Mov. disord.</s0></fA03><fA05><s2>24</s2></fA05><fA06><s2>12</s2></fA06><fA08 i1="01" i2="1" l="ENG"><s1>Using Global Statistical Tests in Long-Term Parkinson's Disease Clinical Trials</s1></fA08><fA11 i1="01" i2="1"><s1>PENG HUANG</s1></fA11><fA11 i1="02" i2="1"><s1>GOETZ (Christopher G.)</s1></fA11><fA11 i1="03" i2="1"><s1>WOOLSON (Robert F.)</s1></fA11><fA11 i1="04" i2="1"><s1>TILLEY (Barbara)</s1></fA11><fA11 i1="05" i2="1"><s1>KERR (Douglas)</s1></fA11><fA11 i1="06" i2="1"><s1>PALESCH (Yuko)</s1></fA11><fA11 i1="07" i2="1"><s1>ELM (Jordan)</s1></fA11><fA11 i1="08" i2="1"><s1>RAVINA (Bernard)</s1></fA11><fA11 i1="09" i2="1"><s1>BERGMANN (Kenneth J.)</s1></fA11><fA11 i1="10" i2="1"><s1>KIEBURTZ (Karl)</s1></fA11><fA14 i1="01"><s1>Division of Oncology Biostatistics, Johns Hopkins University</s1><s2>Baltimore, Maryland</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>5 aut.</sZ></fA14><fA14 i1="02"><s1>Department of Medicine, Rush University Medical Center</s1><s2>Chicago, Illinois</s2><s3>USA</s3><sZ>2 aut.</sZ></fA14><fA14 i1="03"><s1>Department of Biostatistics, Bioinformatics, and Epidemiology, Medical University of South Carolina</s1><s2>Charleston, South Carolina</s2><s3>USA</s3><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ></fA14><fA14 i1="04"><s1>Department of Neurology, University of Rochester</s1><s2>Rochester, New York</s2><s3>USA</s3><sZ>8 aut.</sZ><sZ>10 aut.</sZ></fA14><fA14 i1="05"><s1>U.S. Food and Drug Administration</s1><s2>Silver Spring, Maryland</s2><s3>USA</s3><sZ>9 aut.</sZ></fA14><fA20><s1>1732-1739</s1></fA20><fA21><s1>2009</s1></fA21><fA23 i1="01"><s0>ENG</s0></fA23><fA43 i1="01"><s1>INIST</s1><s2>20953</s2><s5>354000170057120030</s5></fA43><fA44><s0>0000</s0><s1>© 2009 INIST-CNRS. All rights reserved.</s1></fA44><fA45><s0>39 ref.</s0></fA45><fA47 i1="01" i2="1"><s0>09-0431484</s0></fA47><fA60><s1>P</s1></fA60><fA61><s0>A</s0></fA61><fA64 i1="01" i2="1"><s0>Movement disorders</s0></fA64><fA66 i1="01"><s0>USA</s0></fA66><fC01 i1="01" l="ENG"><s0>Parkinson's disease (PD) impairments are multidimensional, making it difficult to choose a single primary outcome when evaluating treatments to stop or lessen the long-term decline in PD. We review commonly used multivariate statistical methods for assessing a treatment's global impact, and we highlight the novel Global Statistical Test (GST) methodology. We compare the GST to other multivariate approaches using data from two PD trials. In one trial where the treatment showed consistent improvement on all primary and secondary outcomes, the GST was more powerful than other methods in demonstrating significant improvement. In the trial where treatment induced both improvement and deterioration in key outcomes, the GST failed to demonstrate statistical evidence even though other techniques showed significant improvement. Based on the statistical properties of the GST and its relevance to overall treatment benefit, the GST appears particularly well suited for a disease like PD where disability and impairment reflect dysfunction of diverse brain systems and where both disease and treatment side effects impact quality of life. In future long term trials, use of GST for primary statistical analysis would allow the assessment of clinically relevant outcomes rather than the artificial selection of a single primary outcome.</s0></fC01><fC02 i1="01" i2="X"><s0>002B17</s0></fC02><fC02 i1="02" i2="X"><s0>002B17G</s0></fC02><fC03 i1="01" i2="X" l="FRE"><s0>Maladie de Parkinson</s0><s2>NM</s2><s5>01</s5></fC03><fC03 i1="01" i2="X" l="ENG"><s0>Parkinson disease</s0><s2>NM</s2><s5>01</s5></fC03><fC03 i1="01" i2="X" l="SPA"><s0>Parkinson enfermedad</s0><s2>NM</s2><s5>01</s5></fC03><fC03 i1="02" i2="X" l="FRE"><s0>Pathologie du système nerveux</s0><s5>02</s5></fC03><fC03 i1="02" i2="X" l="ENG"><s0>Nervous system diseases</s0><s5>02</s5></fC03><fC03 i1="02" i2="X" l="SPA"><s0>Sistema nervioso patología</s0><s5>02</s5></fC03><fC03 i1="03" i2="X" l="FRE"><s0>Test statistique</s0><s5>09</s5></fC03><fC03 i1="03" i2="X" l="ENG"><s0>Statistical test</s0><s5>09</s5></fC03><fC03 i1="03" i2="X" l="SPA"><s0>Test estadístico</s0><s5>09</s5></fC03><fC03 i1="04" i2="X" l="FRE"><s0>Essai longue durée</s0><s5>10</s5></fC03><fC03 i1="04" i2="X" l="ENG"><s0>Long term test</s0><s5>10</s5></fC03><fC03 i1="04" i2="X" l="SPA"><s0>Ensayo larga duración</s0><s5>10</s5></fC03><fC03 i1="05" i2="X" l="FRE"><s0>Essai clinique</s0><s5>11</s5></fC03><fC03 i1="05" i2="X" l="ENG"><s0>Clinical trial</s0><s5>11</s5></fC03><fC03 i1="05" i2="X" l="SPA"><s0>Ensayo clínico</s0><s5>11</s5></fC03><fC03 i1="06" i2="X" l="FRE"><s0>Pronostic</s0><s5>12</s5></fC03><fC03 i1="06" i2="X" l="ENG"><s0>Prognosis</s0><s5>12</s5></fC03><fC03 i1="06" i2="X" l="SPA"><s0>Pronóstico</s0><s5>12</s5></fC03><fC03 i1="07" i2="X" l="FRE"><s0>Traitement</s0><s5>13</s5></fC03><fC03 i1="07" i2="X" l="ENG"><s0>Treatment</s0><s5>13</s5></fC03><fC03 i1="07" i2="X" l="SPA"><s0>Tratamiento</s0><s5>13</s5></fC03><fC07 i1="01" i2="X" l="FRE"><s0>Pathologie de l'encéphale</s0><s5>37</s5></fC07><fC07 i1="01" i2="X" l="ENG"><s0>Cerebral disorder</s0><s5>37</s5></fC07><fC07 i1="01" i2="X" l="SPA"><s0>Encéfalo patología</s0><s5>37</s5></fC07><fC07 i1="02" i2="X" l="FRE"><s0>Syndrome extrapyramidal</s0><s5>38</s5></fC07><fC07 i1="02" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0><s5>38</s5></fC07><fC07 i1="02" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0><s5>38</s5></fC07><fC07 i1="03" i2="X" l="FRE"><s0>Maladie dégénérative</s0><s5>39</s5></fC07><fC07 i1="03" i2="X" l="ENG"><s0>Degenerative disease</s0><s5>39</s5></fC07><fC07 i1="03" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0><s5>39</s5></fC07><fC07 i1="04" i2="X" l="FRE"><s0>Pathologie du système nerveux central</s0><s5>40</s5></fC07><fC07 i1="04" i2="X" l="ENG"><s0>Central nervous system disease</s0><s5>40</s5></fC07><fC07 i1="04" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0><s5>40</s5></fC07><fN21><s1>313</s1></fN21><fN44 i1="01"><s1>OTO</s1></fN44><fN82><s1>OTO</s1></fN82></pA></standard></inist><affiliations><list><country><li>États-Unis</li></country><region><li>Caroline du Sud</li><li>Illinois</li><li>Maryland</li><li>État de New York</li></region></list><tree><country name="États-Unis"><region name="Maryland"><name sortKey="Peng Huang" sort="Peng Huang" uniqKey="Peng Huang" last="Peng Huang">PENG HUANG</name></region><name sortKey="Bergmann, Kenneth J" sort="Bergmann, Kenneth J" uniqKey="Bergmann K" first="Kenneth J." last="Bergmann">Kenneth J. Bergmann</name><name sortKey="Elm, Jordan" sort="Elm, Jordan" uniqKey="Elm J" first="Jordan" last="Elm">Jordan Elm</name><name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G." last="Goetz">Christopher G. Goetz</name><name sortKey="Kerr, Douglas" sort="Kerr, Douglas" uniqKey="Kerr D" first="Douglas" last="Kerr">Douglas Kerr</name><name sortKey="Kieburtz, Karl" sort="Kieburtz, Karl" uniqKey="Kieburtz K" first="Karl" last="Kieburtz">Karl Kieburtz</name><name sortKey="Palesch, Yuko" sort="Palesch, Yuko" uniqKey="Palesch Y" first="Yuko" last="Palesch">Yuko Palesch</name><name sortKey="Ravina, Bernard" sort="Ravina, Bernard" uniqKey="Ravina B" first="Bernard" last="Ravina">Bernard Ravina</name><name sortKey="Tilley, Barbara" sort="Tilley, Barbara" uniqKey="Tilley B" first="Barbara" last="Tilley">Barbara Tilley</name><name sortKey="Woolson, Robert F" sort="Woolson, Robert F" uniqKey="Woolson R" first="Robert F." last="Woolson">Robert F. Woolson</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000C66 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Checkpoint/biblio.hfd -nk 000C66 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PascalFrancis
|étape= Checkpoint
|type= RBID
|clé= Pascal:09-0431484
|texte= Using Global Statistical Tests in Long-Term Parkinson's Disease Clinical Trials
}}
| This area was generated with Dilib version V0.6.23. |  |